Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
New breast cancer study findings have been reported by scientists at Fudan University
May 15th, 2008
"The dosing schedule of docetaxel may affect its clinical activity and toxicity profile. Although triweekly docetaxel has higher antitumor activity but more severe hematological toxicity, weekly docetaxel seems to have less activity or fewer adverse events," scientists in Shanghai, People's Republic of China report. "To evaluate the efficacy and toxicity of biweekly docetaxel and mitoxantrone in patients with advanced breast cancer, the regimen consisting of docetaxel (60 mg/m(2)), and mitoxantrone (8 mg/m(2)) was administered intravenously to 59 patients every 2 weeks, Most (54.2%) of the patients experienced objective responses. The median time to progression for the...
Source: Women's Health Weekly (2008-05-15)
|
